PSKH1

Across TCGA pan-cancer cohorts, PSKH1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PSKH1 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher PSKH1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PSKH1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, LIHC, and UCEC are the cancer types where PSKH1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	IV	0.051	0.600	<.001	12	view →
LIHC	DFS	Median	III,IV	0.076	0.360	.001	12	view →
UCEC	DFS	Median	All	1.000	0.632	.014	10	view →
SKCM	DFS	Median	All	0.087	0.757	<.001	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PSKH1–BLCA (OS)

Open the BLCA breakdown →